Zoetis Expands Poultry Portfolio with Poulvac® Procerta® HVT-IBD-ND

Zoetis Expands Poultry Portfolio with Poulvac® Procerta® HVT-IBD-ND

New recombinant vector vaccine protects against three diseases with one dose

DURHAM, N.C., July 7, 2022 — Zoetis has expanded its poultry vaccine portfolio with the introduction of Poulvac® Procerta® HVT-IBD-ND, a recombinant vector vaccine that provides early, robust protection against Marek’s, infectious bursal and Newcastle disease viruses with one dose. 

“Poulvac Procerta HVT-IBD-ND is the culmination of meticulous research conducted by a team of our top molecular scientists using the most advanced technology available,” said Sing Rong, PhD, research director at Zoetis.

“The vaccine has a unique construction and a strong promoter that helps boost immunogenicity — features that set it apart from other vaccines in the same category,” she said.

The backbone of the new, trivalent vaccine is avirulent herpesvirus of turkey (HVT), which replicates in chickens and is known to be a safe and effective vector for delivering major avian antigens. It is the third recombinant vector vaccine from Zoetis, following the introduction of Poulvac® Procerta® HVT-ND in 2020 and Poulvac® Procerta® HVT-IBD in 2021.

When developing the vaccine, Zoetis scientists started by constructing 43 recombinant prototypes, which were then subjected to rigorous, controlled studies to find the one that provided the best, early immunity. The candidate that was finally selected is the vaccine that is now Poulvac Procerta HVT-IBD-ND.

Onset of immunity

Protection in birds that received the trivalent vaccine in ovo was 90% following intraocular challenge with a virulent infectious bursal disease (IBD) virus at 14 and 21 days of age,[i] Rong said.

The vaccine also proved effective against velogenic Newcastle disease (ND) following in ovo administration, providing 75% protection after a challenge at 14 days of age and 95% protection after challenge at 21 days of age.[ii]

When birds that received Poulvac Procerta HVT-IBD-ND were challenged at 63 days of age with virulent or very virulent IBD[iii] or velogenic  ND viruses, 100% were protected, demonstrating the vaccine’s long duration of immunity, Rong said.[iv],[v],[vi]

Like the other HVT vector vaccines, Poulvac Procerta HVT-IBD-ND has an excellent safety profile and avoids reactions associated with live ND vaccines. It can be administered subcutaneously at hatch as well as in ovo, Rong added.

Cuts losses, labor costs

According to Kalen Cookson, DVM, director of clinical research, Zoetis, the ability to protect against three diseases with one dose has several advantages.

“Most important is the early protection the vaccine provides, which can help prevent costly losses associated with all three diseases,” he said.

“Marek’s disease (MD), IBD and ND viruses are contagious pathogens that lead to poor field performance and condemnations. MD and IBD lead to immunosuppression, which predisposes both young and older birds to secondary infections. With most US flocks now being raised without antibiotics, establishing early, robust immunity through vaccination is essential,” Cookson continued.

In addition, he added, “the high ND protection levels provided by Poulvac Procerta HVT-IBD-ND persist even in the oldest broilers raised today, in contrast to the more short-lived immunity provided by single applications of live ND vaccines.”

A trivalent vaccine simplifies vaccine preparation, and when administered with proven technology such as the Embrex® Inovoject® system, producers can save a considerable amount on labor, he said.

Poulvac Procerta HVT-IBD-ND will begin shipping on July 14, 2022. The vaccine is backed by technical expertise from Zoetis veterinary services and support from the Embrex team.

For more information on Poulvac Procerta HVT-IBD-ND, poultry veterinarians and producers should contact their Zoetis representative or go to poulvacprocerta.com.

About Zoetis

As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After 70 years innovating ways to predict, prevent, detect, and treat animal illness, Zoetis continues to stand by those raising and caring for animals worldwide – from livestock farmers to veterinarians and pet owners. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $7.8 billion in 2021 with approximately 12,100 employees. For more information, visit www.zoetis.com.

Media Contacts:

Julie Groce

Zoetis

919-316-8749

julie.groce@zoetis.com

Joseph Feeks

PR Works

508-274-6497

jfeeks@prworks.net

###

 References

[i] Data on file, Study Report No. B812W-US-18-A07, Zoetis LLC.

[ii] Data on file, Study Report No. B812W-US-18-A06, Zoetis LLC

[iii] Data on file, Study Report No. B814R-US-20-D45, Zoetis LLC.

[iv] Data on file, Study Report No. B814R-US-19-C18, Zoetis LLC.

[v] Data on file, Study Report No. B814R-US-20-D10, Zoetis LLC.

[vi] Data on file, Study Report No. B814R-US-20-C74, Zoetis LLC.

 

 

 

DLV-00019

CONTACT US

1-888-963-8471

Mon–Fri, 8:30am–8:00pm ET

This site is intended for U.S. Animal Healthcare Professionals. The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2022 Zoetis Services LLC. All rights reserved.